---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-016264"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T18:10:11.390367+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Allarity CEO to present company overview at Pharma Partnering Summit US on May 14-15

## Summary
- CEO Thomas H. Jensen will deliver a company overview on stenoparib (dual PARP/WNT inhibitor) and DRP® platform.
- One-on-one meetings will be conducted at the event in San Diego, CA on May 14-15, 2025.
- Participation is a standard business development and licensing conference activity.

## SEC filing metadata
- accession: 0001437749-25-016264
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000143774925016264/0001437749-25-016264-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000143774925016264/allr20250512_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-016264
- JSON: https://secwatch.observer/filing/0001437749-25-016264.json
- Plain text: https://secwatch.observer/filing/0001437749-25-016264.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.